Efficacy of 0.1% Xylometazoline-Hydrochloride nasal decongestant spray in Post-operative sign/symptom relief following Septoplasty: A Prospective-experimental Study.

Efficacy of 0.1% Xylometazoline-Hydrochloride nasal decongestant spray in Post-operative sign/symptom relief following Septoplasty: A Prospective-experimental Study. - Efficacy of 0.1% Xylometazoline-Hydrochloride Nasal Decongestant Spray in Post-septoplasty Sign/Symptom Relief (ENSPS-EPES).

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000052217

Enrollment

120

Registered

2023-09-15

Start date

2022-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-operative relief from signs and symptoms following Septoplasty.

Interventions

0.9% Normal Saline Nasal Spray (Placebo) 0.1% Xylometazoline Hydrochloride Nasal Spray

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 15-60 years undergoing septoplasty for symptomatic deviated nasal septum (DNS) belonging to UH and CGH were included in the study.

Exclusion criteria

Exclusion criteria: Patients not from UH and CGH of age <15 years and >60 years, admitted for revision surgery or trauma or in which septoplasty was performed along with other nasal procedures like turbinate reduction or functional endoscopic sinus surgery or submucosal resection (SMR), history of acute or chronic rhinosinusitis and obstructive sleep apnoea, perforated nasal septum, insufficient nasal valve, granulomatous condition of the nose and sinuses, pregnancy, craniofacial malformation (cleft palate or cleft lip), HIV or any bleeding diathesis condition, malignancy, allergic rhinitis, usage of antihistamines or anticoagulants, and history of allergies to allocated drugs were excluded from the study.

Design outcomes

Primary

Measure	Time frame
Post-operative septoplasty sign/symptom relief using the assigned drug.	—

Secondary

Measure	Time frame
Patient Satisfaction with the assigned drug.	—

Countries

Asia(except Japan)

Contacts

Public ContactMuhammad Hamza Dawood

United Medical and Dental College MBBS

Muhammadhamzadawood86@gmail.com+923303051270

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026